Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 28, 2026; 32(44): 122876
Published online Nov 28, 2026. doi: 10.3748/wjg.122876
Published online Nov 28, 2026. doi: 10.3748/wjg.122876
Table 2 Subgroup analysis of the primary outcome
| Subgroup | Number of responsive/total patients | RR (95%CI) | P value for interaction | |
| FM + LPZ group | P + LPZ group | |||
| All patients | 71/82 | 51/82 | 1.39 (1.15-1.68) | |
| Mood disorders | ||||
| With anxiety/depression | 38/44 | 27/45 | 1.44 (1.10-1.88) | 0.706 |
| No anxiety/depression | 33/38 | 24/37 | 1.34 (1.03-1.75) | |
- Citation: Yin KH, Wang XY, Wang XY, Cheng L, Wang B, Wang QQ, Qiao Y, Tang XR, Yan XJ, Chen SL. Efficacy and safety of neuromodulators combined with proton pump inhibitors for non-erosive reflux disease: A randomized clinical trial. World J Gastroenterol 2026; 32(44): 122876
- URL: https://www.wjgnet.com/1007-9327/full/v32/i44/122876.htm
- DOI: https://dx.doi.org/10.3748/wjg.122876